Pershing Edward, CEO, reported an open-market or private purchase at PROVECTUS BIOPHARMACEUTICALS, INC. involving 34940.000000 shares for an estimated $99998.28. Reported holdings after the transaction were 2613807.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
Form 4 relationship flags and nearby filing context
CEO
The Reporting Person acquired 34,940 shares of Series D-1 Preferred Stock in a private transaction.
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate…
0 other filings
0 recent txs